KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) Leases (2019 - 2025)

Emergent BioSolutions' Leases history spans 7 years, with the latest figure at $10.6 million for Q4 2025.

  • For Q4 2025, Leases fell 9.4% year-over-year to $10.6 million; the TTM value through Dec 2025 reached $10.6 million, down 9.4%, while the annual FY2025 figure was $10.6 million, 9.4% down from the prior year.
  • Leases reached $10.6 million in Q4 2025 per EBS's latest filing, up from $7.2 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $29.7 million in Q1 2021 to a low of $6.6 million in Q1 2025.
  • Average Leases over 5 years is $17.9 million, with a median of $16.0 million recorded in 2023.
  • Peak YoY movement for Leases: rose 21.37% in 2021, then tumbled 56.86% in 2025.
  • A 5-year view of Leases shows it stood at $28.3 million in 2021, then tumbled by 31.45% to $19.4 million in 2022, then fell by 16.49% to $16.2 million in 2023, then dropped by 27.78% to $11.7 million in 2024, then dropped by 9.4% to $10.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Leases are $10.6 million (Q4 2025), $7.2 million (Q3 2025), and $7.7 million (Q2 2025).